{"id":28098,"date":"2019-01-08T00:00:00","date_gmt":"2019-01-08T05:00:00","guid":{"rendered":"http:\/\/ashleydev.com\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/"},"modified":"2020-08-27T11:26:44","modified_gmt":"2020-08-27T15:26:44","slug":"bruce-power-to-produce-lutetium-177-for-cancer-therapy-3","status":"publish","type":"post","link":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/","title":{"rendered":"Bruce Power to produce Lutetium-177 for cancer&nbsp;therapy"},"content":{"rendered":"<p><img decoding=\"async\" class=\"alignright wp-image-20788 size-full\" src=\"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg\" sizes=\"(max-width: 808px) 100vw, 808px\" srcset=\"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg 808w, https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial-300x221.jpg 300w, https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial-768x565.jpg 768w\" alt=\"\" width=\"300\" \/>In late June, Bruce Power joined forces with Isotopen Technologien M\u00fcnchen (ITM) to examine the production of the radioisotope Lutetium-177 at the Bruce Power site.<\/p>\n<p>Lu-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumours and prostate cancer.<\/p>\n<p>The medical-grade radioisotope is used to destroy cancer cells while leaving healthy cells unaffected.<\/p>\n<p>According to the company, the Bruce Power site has the ability to meet global supply needs through 2064, which is the lifespan of the station after refurbishment.<\/p>\n<div id=\"attachment_20789\" class=\"wp-caption alignleft\">\n<p><img decoding=\"async\" class=\"size-full wp-image-20789\" src=\"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/Bruce-Power-site.jpg\" sizes=\"(max-width: 2000px) 100vw, 2000px\" srcset=\"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/Bruce-Power-site.jpg 2000w, https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/Bruce-Power-site-300x200.jpg 300w, https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/Bruce-Power-site-768x512.jpg 768w, https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/Bruce-Power-site-1024x682.jpg 1024w\" alt=\"\" width=\"450\" \/><\/p>\n<p class=\"wp-caption-text\">Bruce Power nuclear generating station<\/p>\n<\/div>\n<p>\u201cBy developing innovative ways to generate these radioisotopes, we help ensure that the medical community has access to a reliable source of medical radioisotopes for Targeted Radionuclide Therapy,\u201d Bruce Power CEO Mike Rencheck said via a press release.<\/p>\n<p>Bruce\u2019s CANDU reactors already produce Cobalt-60, which is used for the sterilization of medical equipment and in a specialized form of cancer treatment called the Gamma Knife.<\/p>\n<p>Bruce Power is part of the Canadian Nuclear Isotope Council (CNIC), which aims to develop collective solutions to maintain Canada\u2019s leadership position in global isotope production. The CNA is also a member of the Council.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In late June, Bruce Power joined forces with Isotopen Technologien M\u00fcnchen (ITM) to examine the production of the radioisotope Lutetium-177 at the Bruce Power site. Lu-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumours and prostate cancer. The medical-grade radioisotope is used to destroy cancer cells while leaving healthy cells unaffected. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[537],"tags":[],"topic":[],"class_list":["post-28098","post","type-post","status-publish","format-standard","hentry","category-talknuclear"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bruce Power to produce Lutetium-177 for cancer therapy - Association nucl\u00e9aire canadienne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bruce Power to produce Lutetium-177 for cancer therapy - Association nucl\u00e9aire canadienne\" \/>\n<meta property=\"og:description\" content=\"In late June, Bruce Power joined forces with Isotopen Technologien M\u00fcnchen (ITM) to examine the production of the radioisotope Lutetium-177 at the Bruce Power site. Lu-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumours and prostate cancer. The medical-grade radioisotope is used to destroy cancer cells while leaving healthy cells unaffected. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Association nucl\u00e9aire canadienne\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/canadanuclear\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-08T05:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-08-27T15:26:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg\" \/>\n<meta name=\"author\" content=\"cna_admin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"cna_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/\"},\"author\":{\"name\":\"cna_admin\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#\\\/schema\\\/person\\\/b0c8179b9b04ade90057bc7a30b2fbd2\"},\"headline\":\"Bruce Power to produce Lutetium-177 for cancer&nbsp;therapy\",\"datePublished\":\"2019-01-08T05:00:00+00:00\",\"dateModified\":\"2020-08-27T15:26:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/\"},\"wordCount\":197,\"publisher\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cna.ca\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/lutetium-editorial.jpg\",\"articleSection\":[\"Talk Nuclear\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/\",\"url\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/\",\"name\":\"Bruce Power to produce Lutetium-177 for cancer therapy - Association nucl\u00e9aire canadienne\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cna.ca\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/lutetium-editorial.jpg\",\"datePublished\":\"2019-01-08T05:00:00+00:00\",\"dateModified\":\"2020-08-27T15:26:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cna.ca\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/lutetium-editorial.jpg\",\"contentUrl\":\"https:\\\/\\\/cna.ca\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/lutetium-editorial.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/2019\\\/01\\\/08\\\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cna.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bruce Power to produce Lutetium-177 for cancer&nbsp;therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/cna.ca\\\/fr\\\/\",\"name\":\"Canadian Nuclear Association\",\"description\":\"The national voice of the Canadian nuclear industry since 1960\",\"publisher\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cna.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#organization\",\"name\":\"Canadian Nuclear Association\",\"url\":\"https:\\\/\\\/cna.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cna.ca\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/cropped-cna-logo-only.png\",\"contentUrl\":\"https:\\\/\\\/cna.ca\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/cropped-cna-logo-only.png\",\"width\":512,\"height\":512,\"caption\":\"Canadian Nuclear Association\"},\"image\":{\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"http:\\\/\\\/www.facebook.com\\\/canadanuclear\",\"https:\\\/\\\/x.com\\\/canadanuclear\",\"https:\\\/\\\/www.instagram.com\\\/canadanuclear\",\"https:\\\/\\\/www.youtube.com\\\/CanadaNuclear\",\"http:\\\/\\\/www.linkedin.com\\\/company\\\/canadian-nuclear-association\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cna.ca\\\/fr\\\/#\\\/schema\\\/person\\\/b0c8179b9b04ade90057bc7a30b2fbd2\",\"name\":\"cna_admin\",\"url\":\"https:\\\/\\\/cna.ca\\\/fr\\\/author\\\/cna_admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bruce Power to produce Lutetium-177 for cancer therapy - Association nucl\u00e9aire canadienne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/","og_locale":"fr_FR","og_type":"article","og_title":"Bruce Power to produce Lutetium-177 for cancer therapy - Association nucl\u00e9aire canadienne","og_description":"In late June, Bruce Power joined forces with Isotopen Technologien M\u00fcnchen (ITM) to examine the production of the radioisotope Lutetium-177 at the Bruce Power site. Lu-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumours and prostate cancer. The medical-grade radioisotope is used to destroy cancer cells while leaving healthy cells unaffected. [&hellip;]","og_url":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/","og_site_name":"Association nucl\u00e9aire canadienne","article_publisher":"http:\/\/www.facebook.com\/canadanuclear","article_published_time":"2019-01-08T05:00:00+00:00","article_modified_time":"2020-08-27T15:26:44+00:00","og_image":[{"url":"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg","type":"","width":"","height":""}],"author":"cna_admin","twitter_misc":{"Written by":"cna_admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/#article","isPartOf":{"@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/"},"author":{"name":"cna_admin","@id":"https:\/\/cna.ca\/fr\/#\/schema\/person\/b0c8179b9b04ade90057bc7a30b2fbd2"},"headline":"Bruce Power to produce Lutetium-177 for cancer&nbsp;therapy","datePublished":"2019-01-08T05:00:00+00:00","dateModified":"2020-08-27T15:26:44+00:00","mainEntityOfPage":{"@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/"},"wordCount":197,"publisher":{"@id":"https:\/\/cna.ca\/fr\/#organization"},"image":{"@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg","articleSection":["Talk Nuclear"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/","url":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/","name":"Bruce Power to produce Lutetium-177 for cancer therapy - Association nucl\u00e9aire canadienne","isPartOf":{"@id":"https:\/\/cna.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/#primaryimage"},"image":{"@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg","datePublished":"2019-01-08T05:00:00+00:00","dateModified":"2020-08-27T15:26:44+00:00","breadcrumb":{"@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/#primaryimage","url":"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg","contentUrl":"https:\/\/cna.ca\/wp-content\/uploads\/2018\/09\/lutetium-editorial.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/cna.ca\/fr\/2019\/01\/08\/bruce-power-to-produce-lutetium-177-for-cancer-therapy-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cna.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Bruce Power to produce Lutetium-177 for cancer&nbsp;therapy"}]},{"@type":"WebSite","@id":"https:\/\/cna.ca\/fr\/#website","url":"https:\/\/cna.ca\/fr\/","name":"Canadian Nuclear Association","description":"The national voice of the Canadian nuclear industry since 1960","publisher":{"@id":"https:\/\/cna.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cna.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/cna.ca\/fr\/#organization","name":"Canadian Nuclear Association","url":"https:\/\/cna.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cna.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/cna.ca\/wp-content\/uploads\/2023\/12\/cropped-cna-logo-only.png","contentUrl":"https:\/\/cna.ca\/wp-content\/uploads\/2023\/12\/cropped-cna-logo-only.png","width":512,"height":512,"caption":"Canadian Nuclear Association"},"image":{"@id":"https:\/\/cna.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["http:\/\/www.facebook.com\/canadanuclear","https:\/\/x.com\/canadanuclear","https:\/\/www.instagram.com\/canadanuclear","https:\/\/www.youtube.com\/CanadaNuclear","http:\/\/www.linkedin.com\/company\/canadian-nuclear-association"]},{"@type":"Person","@id":"https:\/\/cna.ca\/fr\/#\/schema\/person\/b0c8179b9b04ade90057bc7a30b2fbd2","name":"cna_admin","url":"https:\/\/cna.ca\/fr\/author\/cna_admin\/"}]}},"_links":{"self":[{"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/posts\/28098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/comments?post=28098"}],"version-history":[{"count":1,"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/posts\/28098\/revisions"}],"predecessor-version":[{"id":28478,"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/posts\/28098\/revisions\/28478"}],"wp:attachment":[{"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/media?parent=28098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/categories?post=28098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/tags?post=28098"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/cna.ca\/fr\/wp-json\/wp\/v2\/topic?post=28098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}